4-溴-3-氟苯甲酸 | 153556-42-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-3-氟苯甲酸
• 中文别名: 3-氟-4-溴苯甲酸
• 英文名称: 4-bromo-3-fluorobenzoic acid
• 英文别名: 3-fluoro-4-bromobenzoic acid
• CAS: 153556-42-4
• 化学式: C₇H₄BrFO₂
• mdl: MFCD00672932
• 分子量: 219.01
• InChiKey: RMYOGXPGIDWJLU-UHFFFAOYSA-N

物化性质

• 熔点：
  207 °C
• 沸点：
  296.1±25.0 °C(Predicted)
• 密度：
  1.789±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保存方法：密闭于阴凉、通风干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Bromo-3-fluorobenzoic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H319: Causes serious eye irritation
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-fluorobenzoic acid
CAS number: 153556-42-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4BrFO2
Molecular weight: 219.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (4-Bromo-3-fluorobenzoic acid)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-溴-3-氟苯甲酸是一种重要的化工原料，可用于制备多种药物（例如抗癌药物苯扎米特）。

合成方法

4-溴-3-氟苯甲酸可由4-溴-3-氟甲苯通过高锰酸钾氧化得到。

1. 氧化：将100kg 4-溴-3-氟甲苯、120kg水和0.1kg脂肪醇聚醚硫酸钠（AES）依次加入带有搅拌、加热及冷凝回流装置的K-400L搪玻璃反应釜中。加热至沸腾并保持回流状态，然后在搅拌条件下缓慢加入167kg高锰酸钾，继续维持沸腾反应9小时。待回流液不再出现油珠后停止反应。

2. 过滤：将步骤1所得的反应液趁热过滤，得到含目的产物4-溴-3-氟苯甲酸的滤液。

3. 除去高锰酸钾：向步骤2所得的滤液中加入0.1kg亚硫酸钠以去除残留的高锰酸钾。亚硫酸钠的加入量应以溶液紫色退去，呈现透明液体为准。

4. 酸化：在搅拌状态下，逐步向步骤3得到的溶液中加入物质的量浓度为12mol/L的浓盐酸，直至溶液pH值达到2.2后停止加酸。继续反应30分钟。

5. 结晶：在持续搅拌下，将步骤4所得的溶液冷却至2℃，此时析出的晶体即为4-溴-3-氟苯甲酸。操作过程中要不断搅拌以防止形成大块固体。

6. 过滤与洗涤：通过离心分离得到含有4-溴-3-氟苯甲酸晶体的混合液中的滤饼作为粗品，并用纯净水进行洗涤，再利用带有洗涤功能的离心机进一步分离。这样可以制得精制4-溴-3-氟苯甲酸。

7. 干燥：将步骤6制备的4-溴-3-氟苯甲酸固体在75℃下干燥12小时后，得到197kg 4-溴-3-氟苯甲酸，其纯度大于98%。

反应信息

• 作为反应物：
  描述：

  4-溴-3-氟苯甲酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 N,N-二甲基甲酰胺 盐酸 、 草酰氯 、 四甲基乙二胺 、 水 、 氢溴酸 、 potassium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 137.14h， 生成 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzonitrile
  参考文献：
  名称：

  IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS

  摘要：

  本发明涉及嘧啶并咪唑[1,2-b][1,2,4]三嗪类化合物，它们是c-Met的抑制剂，可用于治疗包括癌症在内的与c-Met相关的疾病。

  公开号：

  US20110212967A1
• 作为产物：
  描述：

  4-溴-3-氟甲苯 在 吡啶 、 potassium permanganate 作用下， 以88%的产率得到4-溴-3-氟苯甲酸
  参考文献：
  名称：

  双蛋白法呢基转移酶-香叶基香叶基转移酶-I抑制剂可作为潜在的癌症化学治疗剂。

  摘要：

  一系列新的二芳基醚内酰胺已被确定为非常有效的蛋白法呢基转移酶（FTase）和蛋白geranylgeranyltransferase I（GGTase-I）的双重抑制剂，这些酶涉及Ras的烯丙基化。这些化合物之一与FTase之间形成的配合物的结构已通过X射线晶体学确定。这些化合物是第一个被报道在体内抑制重要癌基因Ki-Ras4B异戊二烯化的化合物。不幸的是，足以达到该终点的剂量迅速致死。

  DOI：

  10.1021/jm020587n

文献信息

• [EN] AZOLE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS D'AZOLE UTILISÉS EN TANT QU'INHIBITEURS DES PIM
  申请人：AMGEN INC

  公开号：WO2012129338A1

  公开（公告）日：2012-09-27

  The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和Ia的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的用途。
• [EN] QUINOLONE DERIVATIVES AS ANTIBACTERIALS<br/>[FR] DÉRIVÉS DE QUINOLONE COMME ANTIBACTÉRIENS
  申请人：NOVARTIS AG

  公开号：WO2016020836A1

  公开（公告）日：2016-02-11

  This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

  这项发明属于药物化学领域，涉及抑制细菌旋转酶的化合物及其制药组合物，这些化合物可用作抑制细菌旋转酶活性和细菌感染的药物，并具有如下所述的Formula (I)的结构。该发明还提供了包含Formula (I)化合物的药物组合物，以及使用这些化合物和组合物治疗细菌感染的方法。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• SUBSTITUTED BIPIPERIDINYL DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318866A1

  公开（公告）日：2016-11-03

  The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  该发明涉及新型取代的双哌啶衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、外周和心脏血管疾病、血栓栓塞疾病和缺血、外周循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及外周和自主神经病变的治疗和/或预防。
• [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE
  申请人：KANCERA AB

  公开号：WO2017108282A1

  公开（公告）日：2017-06-29

  A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

  化合物的化学式（Ia）或（Ib）或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。